Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles.

ABSTRACT:

Purpose

Plasma phosphorylated tau 217 (pTau217) is a promising biomarker for Alzheimer's disease, reflecting both amyloid β (Aβ) and tau positron emission tomography (PET) results. While its diagnostic role is actively being investigated, this study aims to expand its application to staging disease progression and predicting cognitive decline.

Methods

A total of 2,919 participants, primarily diagnosed as Alzheimer's clinical syndrome, were recruited. Plasma pTau217 was measured using the ALZpath assay, and its diagnostic accuracy for binary Aβ/tau (A/T) biomarker profiles and Aβ and tau PET staging was assessed using area under the curve (AUC). Longitudinal Mini-Mental State Examination (MMSE) changes according to plasma pTau217-based staging were analyzed.

Results

Pl

SUBMITTER: Shin D 

PROVIDER: S-EPMC12660329 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature